RxDoctor Payments Data

Jonathan Winston, MD

Nephrology · New York, NYNPI 1861410599

Payments from drug & device makers

$69,271in general payments, 2019–2025

Across 69 payments — averaging $1003.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$25K
  • Gilead$22K
  • Vifor Pharma, Inc.$17K
  • GSK$3K
  • Sarepta Therapeutics, Inc.$2K
  • Scilex Pharmaceuticals Inc.$21
  • plus $16 from 1 others
$224in research payments, 2019–2025

Across 1 payment — averaging $224.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$224

What the payments were for

  • Consulting fees$11,15025%
  • Speaking & faculty fees$27,44063%
  • Travel & lodging$4,36610%
  • Food & beverage$9092%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Bayer14$25,406
Gilead26$21,776
Vifor Pharma, Inc.23$16,866
GSK3$3,386
Sarepta Therapeutics, Inc.1$1,800
Scilex Pharmaceuticals Inc.1$21
Amgen1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$69,271 in reported general payments places this provider in the 90th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$193,770
Medicare patients
574
Services billed
1,745

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProcritEpoetin Alfa71$133,785
FarxigaDapagliflozin Propanediol104$109,636
VeltassaPatiromer Calcium Sorbitex62$102,411
KerendiaFinerenone84$67,491
JardianceEmpagliflozin65$64,510
LokelmaSodium Zirconium Cyclosilicate64$48,552
XphozahTenapanor Hcl12$33,245
EliquisApixaban14$11,647
Calcitriol179$3,197
Potassium Citrate ErPotassium Citrate34$2,631
Sevelamer Carbonate17$1,764
Losartan Potassium133$1,219
Chlorthalidone55$960
Sodium Polystyrene Sulfonate14$824
Metoprolol Succinate25$574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$25,406$67,49184 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 935 nephrology providers in New York.

Other nephrology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →